I understand that close to 10% of all CD patients are under, corticostereoids are nasty, and methotrexate is actually used in chemotherapy, even nastier then corticostereoids, it does more damage in CD than it helps. By the way, they do have some phase III trials for MS and phase II trials for rheumatoid arthritis. In a good market, my target of $70 for BIIB (mentioned earlier today, when suggesting a move from AMGN to BIIB) could be achieved. Too bad BIIB did not reach my $57 or so doubling target earlier today, riding with just one serving (g).....well, I did that "seconds" on BIIB trip three times last week, so no complaints....